

# **Long-term follow-up of a rat model of transient ischemic stroke: protocol design and characterization of neurofunctional and imaging endpoints in the context of stem cell therapy**

Chloé Dumot, Capin Lucille, Hubert Violaine, Ong Elodie, Bolbos Radu, Chauveau Fabien, Emmanuelle Canet-Soulas, Auxenfans Céline, Wiart Marlène  
Lyon 1 university, CarMeN Laboratory, Lyon  
Chloe.dumot@chu-lyon.fr

**Introduction:** Stem cell therapy is a promising ischemic stroke treatment; however, there is little consensus regarding the most appropriate protocol and relevant endpoints for pre-clinical evaluation. The aim of the study was to design a protocol for the long-term assessment of stroke in a rat model of transient middle cerebral artery occlusion (tMCAO) using staircase task (ST) coupled with diffusion tensor imaging (DTI) **Methods:** 25 male Sprague-Dawley rats were trained for the ST and then submitted to surgery. Stem cells were injected at week 1 (W1) in half of tMCAO rats. The ST was performed 4 times a week during 5 weeks. The number of pellets retrieved with forepaws were averaged to obtain one score per week. Side bias (SiB) was calculated as:  $\text{contra}/(\text{ipsi} + \text{contra})$ . MRI was obtained at D3 and D35 post-surgery. Lesion size was measured on T2-weighted imaging. The conventional DTI metrics (AD, RD, MD and FA) were measured in both striatum. **Results:** 10 rats were included, 6 tMCAO and 4 shams. The ipsilateral forepaw of tMCAO rats (corresponding to brain spared side) regained sham level at W2, while the contralateral showed prolonged deficits (SiB at W5: tMCAO  $19 \pm 17\%$  vs sham  $51 \pm 5\%$ ,  $p=0.003$ ). The lesion shrank between D3 and D35 (tMCAO:  $-39 \pm 37\%$ ). DTI metrics AD, RD and MD significantly increased at D35 in the ipsilateral striatum of tMCAO (for MD, D35, ipsi vs contralateral side:  $p=0.001$ ). There was an inverse correlation between MD and SiB at W5 ( $R^2=0.87$ ). There was no difference between treated and untreated group in ST ( SiB at W5: treated  $22 \pm 18\%$  vs untreated  $16 \pm 18\%$ ,  $p=0.34$ ), lesion shrinkage (treated  $-52 \pm 17\%$  vs untreated  $-26 \pm 51\%$ ,  $p=0.22$ ) and DTI metrics (for MD; D35:  $p=0.28$ ). **Conclusion:** We characterized neurofunctional and imaging endpoints for monitoring long-term outcome in tMCAO vs sham rats and checked the innocuity of intracerebral cell administration.